Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Maintenance of a remifentanil infusion during anesthetic emergence has been reported to decrease the incidence of coughing and thereby help to ensure a smooth emergence. It may, however, cause respiratory depression and possibly delay emergence. The purpose of this study was to investigate the effect of different dose of dexmedetomidine infusion on cough suppression during emergence from general anesthesia in patients undergoing thyroid surgery.
American Society of Anesthesiologists physical status I-II adults undergoing elective thyroidectomy under general anesthesia are recruited and randomly allocated to receive dexmedetomidine iv infusion of 0.2μg·kg-1·h-1 (Group D1, n = 100), 0.5μg·kg-1·h-1 (Group D2, n = 100), 0.7μg·kg-1·h-1 (Group D3, n = 100) or saline (Group C, n = 100). Primary outcome is the incidence of coughing during emergence. Second outcomes include severity of coughing, which is assessed using a four-point scale; Ramsay score, Bruggrmann comfort scale score, VAS pain score are recorded. The respiratory rate (RR), heart rate (HR), and mean arterial pressure are also recorded.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dexmedetomidine low dose group | Experimental | Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.2μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery |
|
| Dexmedetomidine median dose group | Experimental | Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.5μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery |
|
| Dexmedetomidine high dose group | Experimental | Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.7μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery |
|
| Control group (normal saline group) | Placebo Comparator | Patients in this group are received saline iv infusion of 5mL·h-1 from incision to 20-30 minutes before the end of surgery |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexmedetomidine Hydrochloride | Drug | Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of coughing during anesthetic emergence | incidence of coughing within 10 minutes after extubation | within 10 minutes after endotracheal extubation |
| Measure | Description | Time Frame |
|---|---|---|
| Ccoughing on a four-point scale during anesthetic emergence | Evaluate the severity of coughing within 10 minutes after extubation by a four-point scale | within 10 minutes after endotracheal extubation |
| Ramsay score during anesthetic emergence |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| SU Min, M.D. | Contact | 86-23-89011068 | ms89011068@163.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China,Chongqing The First Affiliated Hospital of Chongqing Medical University | Recruiting | Chongqing | Chongqing Municipality | 400016 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020927 | Dexmedetomidine |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Normal Saline | Drug | Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery |
|
| Dexmedetomidine Hydrochloride | Drug | Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery |
|
| Dexmedetomidine Hydrochloride | Drug | Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery |
|
Ramsay score 1min, 5min, 10min, and 30min after extubation
| within 30 minutes after endotracheal extubation |
| Bruggrmann comfort scale score | Bruggrmann comfort scale score 30min and 24 hrs after extubation | within 24 hrs after endotracheal extubation |
| VAS pain score | VAS pain score 30min, 24 hrs and 48 hrs after extubation | within 48 hrs after endotracheal extubation |
| Respiratory rate (RR) | Respiratory rate 1min, 5min, 10min, and 30min after extubation | within 30min after endotracheal extubation |
| Heart rate | Heart rate 1min, 5min, 10min, and 30min after extubation | within 30 minutes after endotracheal extubation |
| mean arterial pressure | Mean arterial pressure 1min, 5min, 10min, and 30min after extubation | within 30 minutes after endotracheal extubation |
| D000077324 |
| Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |